<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factors associated with an increased risk of stillbirth and suggested strategies for antenatal fetal surveillance after viability</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factors associated with an increased risk of stillbirth and suggested strategies for antenatal fetal surveillance after viability</h1>
<div class="graphic"><div class="figure"><div class="ttl">Factors associated with an increased risk of stillbirth and suggested strategies for antenatal fetal surveillance after viability</div><div class="cntnt"><table cellspacing="0"><colgroup span="1" width="50%"></colgroup> <colgroup span="2" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Factor</td> <td class="subtitle1">Suggested gestational age to begin antenatal fetal surveillance</td> <td class="subtitle1">Suggested frequency of antenatal fetal surveillance</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Fetal</td> </tr> <tr> <td class="indent1" colspan="3">Growth restriction*</td> </tr> <tr> <td class="indent2">UAD: normal or with elevated impedance to flow in umbilical artery with diastolic flow present; with normal AFI and no other concurrent maternal or fetal conditions</td> <td>At diagnosis<sup>¶</sup></td> <td>Once or twice weekly</td> </tr> <tr> <td class="indent2">UAD: AEDV or concurrent conditions (oligohydramnios, maternal comorbidity [eg, preeclampsia, chronic hypertension])</td> <td>At diagnosis<sup>¶</sup></td> <td>Twice weekly<sup>Δ</sup> or consider inpatient management</td> </tr> <tr> <td class="indent2">UAD: REDV</td> <td>At diagnosis<sup>¶</sup></td> <td>Inpatient management<sup>Δ</sup></td> </tr> <tr> <td class="indent1" colspan="3">Multiple gestation</td> </tr> <tr> <td class="indent2">Twins, uncomplicated dichorionic</td> <td>36 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent2">Twins, dichorionic, complicated by maternal or fetal disorders, such as fetal growth restriction</td> <td>At diagnosis<sup>¶</sup></td> <td>Individualized</td> </tr> <tr> <td class="indent2">Twins, uncomplicated monochorionic-diamniotic</td> <td>32 0/7 weeks<sup>◊</sup></td> <td>Weekly</td> </tr> <tr> <td class="indent2">Twins, complicated monochorionic-diamniotic (ie, TTTS)</td> <td>Individualized</td> <td>Individualized</td> </tr> <tr> <td class="indent2">Twins, monoamniotic</td> <td>Individualized</td> <td>Individualized</td> </tr> <tr> <td class="indent2">Triplets and higher order multiples</td> <td>Individualized</td> <td>Individualized</td> </tr> <tr> <td class="indent1">Decreased fetal movement</td> <td>At diagnosis<sup>Δ</sup></td> <td>Once<sup>§</sup></td> </tr> <tr> <td class="indent1">Fetal anomalies and aneuploidy</td> <td>Individualized</td> <td>Individualized</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Maternal</td> </tr> <tr> <td class="indent1" colspan="3">Hypertension, chronic</td> </tr> <tr> <td class="indent2">Controlled with medications</td> <td>32 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent2">Poorly controlled or with associated medical conditions</td> <td>At diagnosis<sup>¶</sup></td> <td>Individualized</td> </tr> <tr> <td class="indent1" colspan="3">Gestational hypertension/preeclampsia</td> </tr> <tr> <td class="indent2">Without severe features</td> <td>At diagnosis<sup>¶</sup><sup>Δ</sup></td> <td>Twice weekly</td> </tr> <tr> <td class="indent2">With severe features</td> <td>At diagnosis<sup>¶</sup><sup>Δ</sup></td> <td>Daily</td> </tr> <tr> <td class="indent1" colspan="3">Diabetes</td> </tr> <tr> <td class="indent2">Gestational, controlled on medications without other comorbidities</td> <td>32 0/7 weeks</td> <td>Once or twice weekly</td> </tr> <tr> <td class="indent2">Gestational, poorly controlled</td> <td>32 0/7 weeks</td> <td>Twice weekly</td> </tr> <tr> <td class="indent2">Pregestational</td> <td>32 0/7 weeks<sup>¥</sup></td> <td>Twice weekly</td> </tr> <tr> <td class="indent1" colspan="3">Systemic lupus erythematosus</td> </tr> <tr> <td class="indent2">Uncomplicated</td> <td>By 32 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent2">Complicated<sup>‡</sup></td> <td>At diagnosis<sup>¶</sup></td> <td>Individualized</td> </tr> <tr> <td class="indent1">Antiphospholipid syndrome</td> <td>By 32 0/7 weeks<sup>†</sup></td> <td>Twice weekly</td> </tr> <tr> <td class="indent1" colspan="3">Sickle cell disease</td> </tr> <tr> <td class="indent2">Uncomplicated</td> <td>32 0/7 weeks</td> <td>Once or twice weekly</td> </tr> <tr> <td class="indent2">Complicated**</td> <td>At diagnosis<sup>¶</sup></td> <td>Individualized</td> </tr> <tr> <td class="indent2">Hemoglobinopathies other than Hb SS disease</td> <td>Individualized</td> <td>Individualized</td> </tr> <tr> <td class="indent1">Renal disease (Cr greater than 1.4 mg/dL)</td> <td>32 0/7 weeks</td> <td>Once or twice weekly</td> </tr> <tr> <td class="indent1">Thyroid disorders, poorly controlled</td> <td>Individualized</td> <td>Individualized</td> </tr> <tr> <td class="indent1">In vitro fertilization</td> <td>36 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent1" colspan="3">Substance use</td> </tr> <tr> <td class="indent2">Alcohol, 5 or more drinks per week</td> <td>36 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent2">Polysubstance use</td> <td>Individualize</td> <td>Individualized</td> </tr> <tr> <td class="indent1" colspan="3">Prepregnancy BMI</td> </tr> <tr> <td class="indent2">Prepregnancy BMI 35.0 to 39.9 kg/m<sup>2</sup></td> <td>37 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent2">Prepregnancy BMI 40 kg/m<sup>2</sup> or above</td> <td>34 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent1">Maternal age older than 35 years</td> <td>Individualized<sup>¶¶</sup></td> <td>Individualized</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Obstetric</td> </tr> <tr> <td class="indent1" colspan="3">Previous stillbirth</td> </tr> <tr> <td class="indent2">At or after 32 0/7 weeks</td> <td>32 0/7 weeks<sup>ΔΔ</sup></td> <td>Once or twice weekly</td> </tr> <tr> <td class="indent2">Before 32 0/7 weeks of gestation</td> <td>Individualized</td> <td>Individualized</td> </tr> <tr> <td class="indent1" colspan="3">History of other adverse pregnancy outcomes in immediately preceding pregnancy</td> </tr> <tr> <td class="indent2">Previous fetal growth restriction requiring preterm delivery</td> <td>32 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent2">Previous preeclampsia requiring preterm delivery</td> <td>32 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent1">Cholestasis</td> <td>At diagnosis<sup>¶</sup></td> <td>Once or twice weekly</td> </tr> <tr> <td class="indent1">Late term</td> <td>41 0/7 weeks</td> <td>Once or twice weekly</td> </tr> <tr> <td class="indent1" colspan="3">Abnormal serum markers<sup>◊◊</sup></td> </tr> <tr> <td class="indent2">PAPP-A less than or equal to the fifth percentile (0.4 MoM)</td> <td>36 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent2">Second-trimester Inhibin A equal to or greater than 2.0 MoM</td> <td>36 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Placental</td> </tr> <tr> <td class="indent1">Chronic placental abruption<sup>§§</sup></td> <td>At diagnosis<sup>¶</sup></td> <td>Once or twice weekly</td> </tr> <tr> <td class="indent1">Vasa previa</td> <td>Individualized</td> <td>Individualized</td> </tr> <tr> <td class="indent1">Velamentous cord insertion</td> <td>36 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent1">Single umbilical artery</td> <td>36 0/7 weeks</td> <td>Weekly</td> </tr> <tr> <td class="indent1">Isolated oligohydramnios (single deepest vertical pocket less than 2 cm)</td> <td>At diagnosis<sup>¶</sup><sup>Δ</sup></td> <td>Once or twice weekly</td> </tr> <tr> <td class="indent1">Polyhydramnios, moderate to severe (deepest vertical pocket equal to or greater than 12 cm or AFI equal to or greater than 30 cm)</td> <td>32 0/7 to 34 0/7 weeks<sup>¥¥</sup></td> <td>Once or twice weekly</td> </tr> </tbody></table></div><div class="graphic_lgnd">The guidance offered in this table should be construed only as suggestions, not mandates. Ultimately, individualization about if and when to offer antenatal fetal surveillance is advised.</div><div class="graphic_footnotes"><p>AEDV: absent end-diastolic velocity; 
		AFI: amniotic fluid index; 
		BMI: body mass index; 
		Cr; creatinine; 
		MoM: multiples of the median; 
		PAPP-A: pregnancy-associated plasma protein A; 
		REDV: reversed end-diastolic flow; 
		TTTS: twin to twin transfusion syndrome; 
		UAD: umbilical artery Doppler.</p>
<p>* Estimated fetal weight or abdominal circumference less than the 10th percentile.</p>
<p>¶ Or at a gestational age when delivery would be considered because of abnormal test results.</p>
<p>Δ If not delivered.</p>
<p>◊ In addition to routine surveillance for twin–twin transfusion syndrome and other monochorionic twin complications.</p>
<p>§ Repeat if decreased fetal movement recurs.</p>
<p>¥ Or earlier for poor glycemic control or end organ damage.</p>
<p>‡ Such as active lupus nephritis, recent lupus flare, antiphospholipid antibodies with prior fetal loss, anti-RO/SSA or anti-La/SSB antibodies, or thrombosis.</p>
<p>† Individualize, take into consideration obstetric history, number of positive antibodies, and current pregnancy complications.</p>
<p>** Such as maternal hypertension, vaso-occlusive crisis, placental insufficiency, fetal growth restriction.</p>
<p>¶¶ Based on cumulative risk when present with other factors.</p>
<p>ΔΔ Or starting 1 to 2 weeks before the gestational age of the previous stillbirth.</p>
<p>◊◊ If serum screening for aneuploidy is performed, the results may be considered in determining whether antenatal fetal surveillance should be performed.</p>
<p>§§ In individuals who are candidates for outpatient management.</p>
	
	¥¥ Or at diagnosis if diagnosed after 32 0/7 to 34 0/7 weeks.</div><div class="graphic_reference">From: Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion Summary, Number 828. Obstet Gynecol 2021; 137:1148. DOI: <a href="https://journals.lww.com/greenjournal/Fulltext/2021/06000/Indications_for_Outpatient_Antenatal_Fetal.34.aspx" target="_blank">10.1097/AOG.0000000000004408</a>. Copyright © 2021 American College of Obstetricians and Gynecologists. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 138537 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
